Toxicity information regarding brexucabtagene autoleucel is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as severe infections, severe and prolonged cytopenia, hypogammaglobulinemia, cytokine release syndrome, and neurological toxicities.A216188, L15148 Symptomatic and supportive measures are recommended.
Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy have few treatment options.A216153, A216158
More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells. These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen.A216188 Similar to axicabtagene ciloleucel, brexucabtagene autoleucel employs a murine anti-CD19 single-chain variable fragment (scFv) linked to internal CD28- and CD3?-derived co-stimulatory domains.A216148, A216163, L15148 However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in the CAR T cell preparation.L15148
Brexucabtagene autoleucel was granted accelerated approval for the treatment of relapsed and refractory MCL by the FDA on July 24, 2020, and is currently available through Kite Pharma Inc. under the tradename TECARTUS.L15148
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brexucabtagene autoleucel. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brexucabtagene autoleucel. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Brexucabtagene autoleucel. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brexucabtagene autoleucel. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Quinisocaine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Brexucabtagene autoleucel is combined with Etrasimod. |